Genzyme's Gene Therapy IP Land Grab
Executive Summary
By acquiring Cell Genesys Inc. in a $350 million stock swap, Genzyme Corp. hopes it has found a way to hedge one set of development risks--including potential generic competition for its biggest product, while at the same time doubling up on a technology bet in another area.